Tiejun J. Yang

Zhengzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer.

Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer.

Journal: The New England journal of medicine

Published: October 22, 2025

Efficacy and Safety of BL-B01D1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma: A Phase II Clinical Trial.

Efficacy and Safety of BL-B01D1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma: A Phase II Clinical Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: October 08, 2025

Diet-metabolism-transcription axis modulates the sensitivity to CDK4/6 inhibitors through RB1 in prostate cancer.

Diet-metabolism-transcription axis modulates the sensitivity to CDK4/6 inhibitors through RB1 in prostate cancer.

Journal: Cell reports

Published: June 12, 2025

Prophylactic laxative use for postoperative constipation in urological cancer: a real-world cohort study.

Prophylactic laxative use for postoperative constipation in urological cancer: a real-world cohort study.

Journal: World journal of urology

Published: June 06, 2025

Distinct Clinicopathological Features of HER2-Negative, HER2-Low, and HER2-Overexpressing Urothelial Carcinoma in a Large Chinese Cohort.

Distinct Clinicopathological Features of HER2-Negative, HER2-Low, and HER2-Overexpressing Urothelial Carcinoma in a Large Chinese Cohort.

Journal: Cancer medicine

Published: June 06, 2025

ITGB4 up-regulated by STAT3 reduces the sensitivity of bladder cancer to cisplatin by suppressing p53.

ITGB4 up-regulated by STAT3 reduces the sensitivity of bladder cancer to cisplatin by suppressing p53.

Journal: British journal of cancer

Published: March 18, 2025

Lactylation prognostic signature identifies DHCR7 as a modulator of chemoresistance and immunotherapy efficacy in bladder cancer.

Lactylation prognostic signature identifies DHCR7 as a modulator of chemoresistance and immunotherapy efficacy in bladder cancer.

Journal: Frontiers in immunology

Published: March 05, 2025

High-glucose-associated YTHDC1 lactylation reduces the sensitivity of bladder cancer to enfortumab vedotin therapy.

High-glucose-associated YTHDC1 lactylation reduces the sensitivity of bladder cancer to enfortumab vedotin therapy.

Journal: Cell reports

Published: November 03, 2024

Case report: Isolated eyelid metastasis of ccRCC 5 years after receiving radical nephrectomy.

Case report: Isolated eyelid metastasis of ccRCC 5 years after receiving radical nephrectomy.

Journal: Frontiers in oncology

Published: October 15, 2023

Clinical study of renal artery cold perfusion combined with laparoscopic nephron retention in the treatment of complex renal angiomyolipoma.

Clinical study of renal artery cold perfusion combined with laparoscopic nephron retention in the treatment of complex renal angiomyolipoma.

Journal: Frontiers in oncology

Published: May 10, 2023

Case report: Gemcitabine intravesical hyperthermic infusion combined with tislelizumab in muscle invasive bladder urothelium carcinoma.

Case report: Gemcitabine intravesical hyperthermic infusion combined with tislelizumab in muscle invasive bladder urothelium carcinoma.

Journal: Frontiers in oncology

Published: October 06, 2022

Tumor Expression Profile Analysis Developed and Validated a Prognostic Model Based on Immune-Related Genes in Bladder Cancer.

Tumor Expression Profile Analysis Developed and Validated a Prognostic Model Based on Immune-Related Genes in Bladder Cancer.

Journal: Frontiers in genetics

Published: April 18, 2021

Showing 1-12 of 21

Last Updated: 09/26/2026